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Abstract 
________________________________________________________________________ 
 
Objective:  To review measures of patient reported outcomes (PROs) that can show 
whether a treatment for age-related macular degeneration also provides patient-perceived 
benefits.  Additionally, to look at health economic measurements currently being used to 
develop cost-effectiveness models for age-related macular degeneration.  
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Introduction 
________________________________________________________________________ 
 
Blindness has been recognized by WHO (World Health Organization) as one of the 
handicaps that most adversely affects individuals, the family and society.  Visual 
impairment has a serious impact on older adults’ ability to perform daily activities, 
measurably interfering with their ability to live independently1.  It is a common reason for 
people to restrict their driving, a highly valued activity for most individuals.  The loss of 
that ability can greatly reduce a person’s sense of independence and well-being2.  Visual 
impairment has also been associated with reduced survival in a population-based 
survey3.  Foremost, the loss of vision has been and remains one of the most feared 
chronic disabilities.  As early as 1973, WHO decreed that elimination of avoidable 
blindness was justified not only from a humanitarian point of view but also from a social 
and economic perspective. 
 
Age-related macular degeneration (AMD) is the leading cause of blindness and severe 
vision loss in older persons within predominantly white populations of the industrial 
world4.  AMD has a profound effect on patient’s lives, and the disability and emotional 
impact associated with advanced AMD can be compared to other serious chronic 
diseases5.  A study presented at the 2002 American Academy of Ophthalmology showed 
that one-third of patients with recently diagnosed AMD were clinically depressed and 
their depression severity was proportional to the level of visual function (Solomon, AAO 2002).  
Two-thirds of AMD patients with uncorrected vision reported emotional distress 
compared to only 2% of those patients with corrected vision. 
 
AMD falls within the overall category of macular disease (MD) that includes such 
disorders as age-related maculopathy, macular dystrophy and several acquired macular 
disorders.  Symptoms are mainly due to a loss of central vision, which is required for 
activities such as reading, driving and recognizing faces.  But since peripheral vision is 
not involved, people do not go completely blind from macular disease alone.  AMD is the 
most common condition affecting the macula and is divided into two types.  The dry (or 
nonexudative) form affects about 90% of those with the disease; its progression is 
relatively slow, it is usually symmetrical with a gradual loss of function of the visual cells 
in the macular region, and its cause is poorly understood.  The wet (or exudative) form 
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makes up most of the remaining 10% of patients and although rarer, accounts for nearly 
90% of all severe visual loss from AMD6,7. 
  
Many new forms of treatment for AMD are on the horizon.  Anecortave acetate currently 
under development by Alcon Research Ltd. for the predominantly classic form of wet 
AMD is just one example8.  The efficacy and safety of new treatments such as 
anecortave acetate will need to be proven with traditional clinical endpoints.  However, 
healthcare payers will also look for measures of patient reported outcomes (PROs) that 
can show whether the treatment also provides patient-perceived benefits.  The addition 
of PRO measures to clinical trials has not been standard practice, but the trend is slowly 
moving in that direction.  In addition, healthcare payers look for assessments of the 
impact of interventions on medical and non-medical future costs.  The following sections 
describe quality of life and health economic measures that have been included in the 
anecortave acetate clinical trials to help decision-makers within the healthcare systems 
allocate resources more effectively 
 
Quality of Life Measurements in MD 
________________________________________________________________________ 
 
Questions that ask specifically about how eyesight affects aspects of life are included in 
vision function questionnaires (which are not, in our view, quality of life [QoL] measures) 
such as the NEI-VFQ519 and NEI–VFQ2510, the Activities of Daily Vision Scale (ADVS)11 
and the 14-item Visual Function Questionnaire (VF-14)12.  The scores from these 
instruments are easier to interpret and more closely correlate with measures of vision 
than the scores from more generic health status instruments such as the SF-3613 and 
the EuroQoL14.  However, the correlation coefficient between NEI-VFQ distance or far 
vision sub-scale scores and distance visual acuity is 0.66 at best15.  Other aspects of 
vision, such as contrast sensitivity and stereoacuity may also influence the scores16 but 
do not give the complete picture.  Professor Clare Bradley and Dr. Jan Mitchell, health 
psychologists at Royal Holloway in the UK, argue that these measures of functional 
status (e.g. how well a person judges he or she can read normal print) do not effectively 
capture the experience of living with MD or its impact on QoL.  That is, to measure the 
impact of MD on quality of life, one needs to consider aspects of life of relevance to the 
individual concerned, and to measure both the impact of the condition on each aspect of 
life and the importance of each aspect of life to their QoL.  For example, an individual 
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may report that, if they did not have MD, their physical appearance (including clothes 
and grooming) would be very much better, but that physical appearance is not at all 
important to them. Thus, although functional status in terms of self-care might be 
impaired, it has no impact on QoL. For another person, physical appearance may be 
very important and so the same impact score alone (as in a functional status 
questionnaire) may not fully reflect the distress experienced by that person. The Royal 
Holloway team has developed individualized QoL measures for a number of medical 
conditions including MD that allow relevance and importance of different aspects of life 
to be considered for each respondent as well as the impact of MD on relevant aspects of 
life 
 
In 1999 the Royal Holloway team, supported by Alcon Research Ltd., initiated 
development work on a new PRO instrument named the Macular Disease Quality of Life 
(MacDQoL) instrument.  The result of this work is an instrument that is an individualized 
measure of the impact of MD on QoL17.  It is based on the individualized ADDQoL 
measure for people with diabetes18, which in turn was influenced by work on the SEIQoL 
generic interview measure of quality of life19.  The MacDQoL, however, addresses 
aspects of life important to people with MD.  Members of local Macular Disease Society 
groups in the UK contributed to the design work and participated in focus groups.  A 
postal pilot test of the MacDQoL was carried out with a nationwide sample of members 
of the MD Society.  Still other members helped to investigate whether MacDQoL scores 
were comparable when different methods of completing the questionnaire were used 
(pen and paper or telephone interview)(Mitchell, Qual Life Res 2004 Abstract). 
 
The MacDQoL has a single opening overview question about quality of life per se (7-
point scale, range +3 [excellent], through 0 [neither good nor bad] to – 3 [extremely 
bad]), and a second overview item about the impact of MD on QoL (5-point scale, range 
–3 [very much better], through 0 [the same] to +1 [worse]).  The remaining items cover 
different domains or aspects of life that may be 1) negatively impacted by MD and may 
be 2) important for an individual’s QoL. Several items have a ‘not applicable’ option (e.g. 
work, holidays). Impact is scored on a 5-point scale (range –3 [very much better] through 
0 [the same] to +1 [worse]). Importance is scored on a 4-point scale (range 3 [very 
important] to 0 [not at all important]). Impact and importance scores are multiplied to give 
a weighted impact score. A single, average weighted impact score is obtained by 
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calculating a mean of the weighted impact scores of all applicable items.  Domains were 
selected with reference to the literature and after consultation with MD patients.  The 
domain items in the MacDQoL currently in use are shown in Table 1.  Negative wording 
was used in some items (e.g time taken) in order to keep the grammatical structure as 
simple and clear as possible. Seventeen new language versions of the MacDQoL were 
produced by specialists in linguistic validation work at Mapi in Lyon, France in 
collaboration with the Royal Holloway team.  The questionnaires are currently being 
used to collect QoL data from patients enrolled in the anecortave acetate phase III 
clinical trials. 
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Table 1:  MacDQoL items (and response options) retained following psychometric 
evaluation 
No. Item Wording Response Options 
A In general, my present quality of life is: Excellent – extremely bad 
B If I did not have MD, my quality of life would be Very much better - worse 
 Domain items 
Each Item begins with the phrase: 
If I did not have MD ……….. 
 
1 I could handle my household tasks: Very much better – worse 
2 I could handle my personal affairs (letters, bills, etc): Very much better – worse 
3 My experience of shopping would be: Very much better – worse 
4* My working life and work-related opportunities would be: Very much better – worse 
5 My close personal relationship (e.g., marriage, living 
companion, steady relationship), now or in the future, would 
be: 
Very much better – worse 
6* My family life would be: Very much better – worse 
7 My friendships and social life would be: Very much better – worse 
8 My physical appearance (including clothes and grooming) 
would be: 
Very much better – worse 
9 Physically, I could do: Very much more - less 
10 I could get out and about (e.g. on foot, or by car, bus or train) Very much better – worse 
 11* My holidays would be: Very much better – worse 
12 I could pursue or enjoy my leisure activities (e.g. reading, TV, 
radio, cinema): 
Very much better – worse 
13 I could pursue or enjoy my hobbies and interests (e.g. sport, 
crafts, pets, gardening): 
Very much better – worse 
14 My self-confidence would be: Very much better – worse 
15 If I did not have MD, my motivation to achieve things would 
be: 
Very much better – worse 
 16 The way people in general react to me would be: Very much better – worse 
17 My feelings about the future (e.g. worries, hopes) would be: Very much better – worse 
18 My financial situation would be: Very much better – worse 
19 I would have to depend on others (when I do not want to): Very much less - more 
20 I could do things for others as I wish: Very much better – worse 
21 I would have mishaps or would lose things: Very much less - more 
22 I could enjoy meals: Very much more - less 
23 The time it takes me to do things would be: Very much less - more 
24 I could enjoy nature: Very much more - less 
 *indicates items for which an opening question allows the respondent to indicate that the 
item is not applicable to them, and move on to the next item. 
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In 2004, data from this trial have been used to investigate the reliability and validity of 
the MacDQoL in the new language versions.  Some refinement of items has been made 
shortening the questionnaire without losing important information and it is apparent that 
items 12 and 13, concerning leisure activities and hobbies and interests, can be merged 
to form a single item.  Changes made were supported by data from a parallel validation 
study in Nottingham, UK to evaluate the MacDQoL measures outside of a clinical trial20  
This study includes an investigation of the MacDQoL’s responsiveness to change in 
severity of MD over a period of one year.  People with both wet and dry MD participating 
in the study have a wide range of severity and years of disease experience.  Baseline 
data from the Nottingham study already demonstrate the MacDQoL’s suitability for use 
with all kinds of MD and not just those with wet MD who are being included in the clinical 
trial. 
 
Questionnaires based on the principles of judgement analysis, including the MacDQoL, 
tend to be longer than other questionnaires because there are two aspects to each 
domain (impact and importance). However, for most purposes this is justified by the 
value of the information gained. For some purposes it may be sufficient to use the MD-
specific overview item (which correlates 0.58 with the average weighted impact score20) 
where brevity is of prime importance. Participants need to have been aware of having 
the condition for long enough to have a view of the impact of MD on their QoL before 
they can reasonably be expected to complete the questionnaire. This would also be true 
of many if not all components of visual function measures. Whereas it is currently   
fashionable to use Rasch analysis in the development of questionnaires and scales, the 
method is not appropriate for the MacDQoL.  Rasch analysis requires a simple scoring 
scale and it does not lend itself to the more complex scoring system of the MacDQoL. 
The Rasch method may lead to the elimination of a number of items and this would 
damage the face and content validity of the measure, which the designers consider to be 
of primary importance.  
 
In addition to a disease-specific PRO measure, a generic measure of psychological well-
being, the 12-item Well-being Questionnaire (W-BQ12), has been included in the phase 
III trial.  The original, generic 28-item W-BQ was designed in 1982 for use in a World 
Health Organization study of new treatments for the management of diabetes and was 
developed to provide a 22-item measure of depressed mood, anxiety, energy and 
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positive well-being21.  Considerable data have since been reported on the instrument’s 
validity, sensitivity to change and reliability in diabetes22, healthy relatives of people with 
diabetes(Hendrieckx, PhD thesis, Royal Holloway 2001), and in other conditions such as growth hormone 
deficiency23.  Additionally, the instrument has been successfully translated and validated 
in many European languages22, 24.  Research to create a Japanese version of the W-BQ 
has resulted in a shorter version (12 items; 5 minutes to administer) of the instrument 
which has been supported by detailed work on the Dutch version 25, 26 and confirmed in 
many other languages22, 27. 
 
This W-BQ12 generic tool improves on many previous generic tools including the 
Psychological General Well-being Index23 and the well-being subscale of the Medical 
Outcomes Short-Form 36, SF-3619, 28 by its well-balanced selection of items (equal 
numbers of positive and negative items), clear factor structure and brevity.  In improving 
the balance of the positively and negatively worded items, the factor structure was 
improved.  Three 4-item sub-scales make up the W-BQ12 (i.e., negative well-being, 
energy, positive well-being) and a total general well-being score can also be computed.  
The negative well-being subscale includes two items each from the previous depression 
and anxiety subscales, all four of which are negatively worded.  These balance the 
positive well-being subscale which includes 4 of the previous 6 positive well-being items 
all of which are positively worded.  The energy subscale remains unchanged from the 
W-BQ22 with 2 positively worded and 2 negatively worded items.  The W-BQ12 was 
incorporated into the UK Macular Disease Society Questionnaire to provide 
psychometric data in this patient population.  The survey data were published in 200129, 
30. 
 
Health Economic Measurements in AMD 
________________________________________________________________________ 
 
Health economic measures have also been included in the phase III trials that focus on 
the economic impact of the disease.   It has been estimated that the annual worldwide 
productivity cost of blindness was $168 billion based on 1993 data for prevalence rates, 
gross domestic products and populations 31.  More recent studies have also documented 
the large burden of blindness and visual impairment on the social systems of developed 
countries around the world 32, 33.  These costs will increase dramatically in the future as 
populations age. 
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Decreased vision can lead to changes in occupation, missed time from work, increased 
need for patient caregivers (e.g., family, friends, hired help), and changes in patients’ 
functional abilities affecting activities of daily living.  Moreover, different treatments can 
have different outcomes that may impact on the direct and indirect treatment costs over 
time. Economic questions have been included in the phase III clinical trials that will 
collect data to help decision-makers evaluate the economic impact of treating this 
disease with the various therapies studied. 
 
In addition to collecting economic data from clinical trials, a survey of individuals in the 
US with AMD was initiated via a questionnaire sent to individuals on the mailing list of 
the Macular Degeneration Partnership, a support organization for AMD patients.  Over 
800 individuals completed the survey providing data on the use of assistive services and 
supports.  This study also explored how the level of visual impairment impacted on the 
use and cost of these services and supports.  Non-medical direct costs for services and 
devices ranged from $506 to $1,619 depending on the visual acuity level.  However, 
more significantly, indirect costs associated with the care provider ranged from $225 to 
$47,086 depending on the visual acuity level.  A paper describing these results has been 
submitted for publication and they will be used in future economic models (Schmier, Submitted to 
Retina  2005) 
 
Additional studies have been completed in Europe to look at the consequences of 
blindness and the results have been published or submitted for publication34, 35, 36.  In 
1998 and 1999, the French National Institute for Statistics and Economic Studies 
conducted two national surveys, the first in institutions and the second at home, in order 
to assess the prevalence of various handicaps and their consequences in terms of 
disability and dependence.  A questionnaire dedicated to vision was inserted and the 
individuals could declare themselves as blind (light perception at best) or visually 
impaired (shape perception at least).  The basic finding was that blind and visually 
impaired individuals meet difficulties when performing most of their daily activities 
regardless of their age, the number of people available to assist them, or the presence of 
other handicaps (motor, cerebral, etc.).  Based on these and other results, non-medical 
costs were calculated at the national level and compared to medical costs which showed 
that most of the cost of blindness is outside the healthcare system. 
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Currently, photodynamic therapy (PDT), intravitreal injection with pegaptanib and laser 
photocoagulation are the only FDA approved treatments available for individuals with 
choroidal neovascularization (CNV) secondary to AMD.  Economic models examining 
the cost-effectiveness of many of these treatments already exist in the literature37, 38, 39.  
These economic models support the cost-effectiveness of laser photocoagulation and 
question the cost-effectiveness of PDT at least for individuals with poor vision or whose 
macular lesions were not purely classic.  The quality of life and health economic 
measures we have included in the anecortave acetate clinical trials will help healthcare 
payers more effectively compare this new intervention for AMD with currently used 
treatments. 
 
In the field of AMD, researchers increasingly come up against the physio-pathology of 
aging.  The next innovations are expected to be more costly but to have improved 
efficacy.  By postponing the onset of visual impairment, savings will be realized within 
the healthcare system but mainly outside of it.  The resources required to bring the next 
generation of AMD therapeutic successes to market will be considerable and the global 
economics of visual impairment will need to be considered.  Recently completed studies 
will provide data to cover many dimensions of AMD economics.  By showing the 
complete cost of advancing AMD, healthcare payers will have the opportunity to make 
true comparisons between new treatments with current therapy.  In the end they will be 
able to make better reimbursement decisions based on the overall costs including the 
psychosocial and financial costs to patients. 
 
Method of Literature Search 
 
Our literature search included the following databases: Pubmed, Science Direct, 
Psychinfo, Medline, PDR, USP, Agricola, Applied Science & Technology, Biosis, 
Chembank, Drug Info FullText, eFacts, Embase, IPA, Life Sciences, NERAC, 
PharmaProjects, and Stedman’s Medical Dictionary.  References have been included 
spanning the years 1991-2005.  The search terms included ‘visual impairment’, ‘low 
vision’, ‘macular degeneration’, ‘visual function’, ‘functional status’, ‘quality of life’, ‘cost 
of blindness’ and ‘cost-effectiveness’.  In addition, we obtained articles cited in the 
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reference lists of other papers.  Articles published in languages other than English were 
not considered. 
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